Abstract:Background: Viral resistance to existing inhibitors and the time-dependent effectiveness of neuraminidase inhibitors have limited the number of antivirals that can be used for prophylaxis and therapeutic treatment of severe influenza infection. Thus, there is an urgent need to develop new drugs to prevent and treat influenza infection. Objective: The aim of this study was to design and synthesize a novel series of 2-ureidonicotinamide derivatives, and evaluate their anti-IAV activities. Furthermore, we predicted the abilities of these compounds inhibiting PA-PB1 subunit and forecasted the docking poses of these compounds with RNA polymerase protein (PDB ID 3CM8). Method: The novel designed compounds were synthesized using classical methods of organic chemistry and tested in vitro for their abilities inhibiting RNP and against influenza A virus. In addition, the 23 synthesized molecules were subjected to the generated pharmacophore Hypo1 to forecast the activity target PA-PB1 subunit of RNA polymerase. The ADMET pharmacokinetic parameters were calculated by the ADMET modules in Discovery Studio 2016. The docking results helped us to demonstrate the possible interactions between these compounds with 3CM8. Results: The synthesized 2-ureidonicotinamide derivatives were characterized as potent anti-influenza inhibitors. The target compounds 7b and 7c demonstrated significant antiviral activities, and could be considered as novel lead compounds of antiviral inhibitors. In addition, compound 7b revealed suitable ADME properties expressed, and might be a significant RNA polymerase inhibitor targeting PA-PB1 subunit based on the predictable results and the docking results. Conclusion: This study revealed a novel series of compounds that might be useful in the search for an effective drug against influenza virus.

Discovery of Multiple Lead Compounds As M2 Inhibitors Through the Focused Screening of a Small Primary Amine Library

Discovery of multiple lead compounds as M2 inhibitors through the screening of a focused library of scaffold-hops

Identification of Hits As Matrix-2 Protein Inhibitors Through the Focused Screening of a Small Primary Amine Library

New Strategy for High Throughput Screening of Anti-Influenza Virus M2 Ion Channel Inhibitors.

Insights from Investigating the Interactions of Adamantane-Based Drugs with the M2 Proton Channel from the H1N1 Swine Virus

Potent Inhibitor Design Against H1N1 Swine Influenza: Structure-Based and Molecular Dynamics Analysis for M2 Inhibitors from Traditional Chinese Medicine Database.

Virtual Screening and Molecular Growth Guide the Design of Inhibitors for the Influenza Virus Drug-Resistant Mutant M2-V27A/S31N.

Molecular dynamics simulation directed rational design of inhibitors targeting drug-resistant mutants of influenza A virus M2.

Heterodimers of Histidine and Amantadine As Inhibitors for Wild Type and Mutant M2 Channels of Influenza A

Antiviral Mechanisms and Preclinical Evaluation of Amantadine Analogs that Continue to Inhibit Influenza A Viruses with M2 -Based Drug Resistance

Molecular Dynamics Analysis of Potent Inhibitors of M2 Proton Channel Against H1N1 Swine Influenza Virus

Approaches for discovery of small-molecular antivirals targeting to influenza A virus PB2 subunit

Design and synthesis of pinane oxime derivatives as novel anti-influenza agents

Identification of entry inhibitors with 4-aminopiperidine scaffold targeting group 1 influenza A virus

Design, synthesis, and biological activity of a novel series of 2-ureidonicotinamide derivatives against influenza A virus

Exploring Ugi-Azide Four-Component Reaction Products for Broad-Spectrum Influenza Antivirals with a High Genetic Barrier to Drug Resistance

New small-molecule drug design strategies for fighting resistant influenza A.

Identification of the Imidazo[1,2- a]pyrazine Derivative A4 as a Potential Influenza Virus Nucleoprotein Inhibitor

Potent Anti-Influenza Synergistic Activity of Theobromine and Arainosine

Anti-influenza virus activities and mechanism of antrafenine analogs

Isocyanides As Influenza A Virus Subtype H5N1 Wild‐Type M2 Channel Inhibitors